Friday, 20 September 2019

FDA approves oral diabetes drug from Novo Nordisk

FDA approves oral diabetes drug from Novo NordiskThe U.S. Food and Drug Administration on Friday approved an oral version of Novo Nordisk's diabetes drug semaglutide, a boost for the Danish drugmaker, which hopes to transform the market by offering patients a noninjectable treatment.




No comments:

Post a Comment